<DOC>
	<DOCNO>NCT02379663</DOCNO>
	<brief_summary>This prospective study compare oral direct factor Xa inhibitor LMWH thromboprophylaxis patient undergoing THA .</brief_summary>
	<brief_title>Prophylaxis Deep Vein Thrombosis Following Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Femoral Neck Fractures</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male female without childbearing potential age ≥20 year schedule elective primary THA recent history active bleeding VTE know genetic disorder associate bleeding tendency condition relate increase risk bleed persistent blood pressure ≥160mmHg systolic and/or ≥100 mmHg diastolic baseline myocardial infarction cerebrovascular accident within three month schedule surgery major surgery prior three month renal insufficiency creatinine clearance &lt; 60mL/min , hepatic failure combine coagulopathy , thrombocytopenia ( platelet &lt; 100,000/mm³ ) , plan indwell epidural catheter &gt; 6 hour end surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>